Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Other Accumulated Expenses (2016 - 2023)

Perspective Therapeutics' Other Accumulated Expenses history spans 13 years, with the latest figure at $480000.0 for Q4 2023.

  • For Q4 2023, Other Accumulated Expenses fell 15.94% year-over-year to $480000.0; the TTM value through Dec 2023 reached $480000.0, down 15.94%, while the annual FY2023 figure was $480000.0, 15.94% down from the prior year.
  • Other Accumulated Expenses for Q4 2023 was $480000.0 at Perspective Therapeutics, up from $24000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $571000.0 in Q4 2022 and bottomed at $15000.0 in Q1 2023.
  • The 5-year median for Other Accumulated Expenses is $96500.0 (2020), against an average of $127300.0.
  • The largest annual shift saw Other Accumulated Expenses skyrocketed 454.37% in 2022 before it tumbled 84.04% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $89000.0 in 2019, then rose by 13.48% to $101000.0 in 2020, then rose by 1.98% to $103000.0 in 2021, then surged by 454.37% to $571000.0 in 2022, then fell by 15.94% to $480000.0 in 2023.
  • Per Business Quant, the three most recent readings for CATX's Other Accumulated Expenses are $480000.0 (Q4 2023), $24000.0 (Q3 2023), and $20000.0 (Q2 2023).